⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8524652 | 0.80 | — | — | |
| SCHEMBL5433994 | 0.67 | — | — | |
| SCHEMBL3739121 | 0.65 | — | — | |
| SCHEMBL5434221 | 0.65 | — | — | |
| SCHEMBL11214931 | 0.63 | — | — | |
| SCHEMBL1438699 | 0.62 | — | — | |
| SCHEMBL8355288 | 0.62 | — | — | |
| SCHEMBL16178998 | 0.60 | — | — | |
| Water SCHEMBL8592866 | 0.58 | — | — | |
| SCHEMBL11755943 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040203050-A1 | Polymer arrays and methods of using labeled probe molecules to identify and quantify target molecule expression | REICH NORBERT (US) | 2004-10-14 | — | — | US | claimed |
| CN-118108623-A | Preparation method of organic nitrogen oxide | 天津科技大学 | 2024-05-31 | — | — | CN | disclosed |
| EP-3049409-A1 | ETHYNYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-08-03 | — | — | EP | disclosed |
| EP-2367431-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2015044075-A1 | ETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-02 | — | — | WO | disclosed |
| US-8846693-B2 | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8329656-B2 | Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders | SWITCH BIOTECH AG (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8268785-B2 | Such as tadalafil or sildenafil; vitiligo; use in combination with Pimecrolimus, Tacrolimus, or Cyclosporin A | SWITCH BIOTECH AG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20110142956-A1 | USE OF A PDE 5 INHIBITOR FOR TREATING AND PREVENTING HYPOPIGMENTARY DISORDERS | PEUKER HEIDEMARIE | 2011-06-16 | — | — | US | disclosed |
| EP-1759700-B1 | Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders | SWITCH BIOTECH LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2006018088-A1 | USE OF A PDE 5 INHIBITOR FOR TREATING AND PREVENTING HYPOPIGMENTARY DISORDERS | SWITCH BIOTECH AG (DE) | 2006-02-23 | — | — | WO | disclosed |
| US-20040203050-A1 | Polymer arrays and methods of using labeled probe molecules to identify and quantify target molecule expression | REICH NORBERT (US) | 2004-10-14 | — | — | US | disclosed |
| US-20040072746-A1 | Inhibitors of monocarboxylate transport | ASTRAZENECA AB (SE) | 2004-04-15 | — | — | US | disclosed |
| EP-0975636-B1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE-4,6-DIONES AS T-CELL PROLIFERATION INHIBITORS | ASTRAZENECA AB (SE) | 2003-07-23 | — | — | EP | disclosed |
| EP-0975636-B1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE-4,6-DIONES AS T-CELL PROLIFERATION INHIBITORS | ASTRAZENECA AB (SE) | 2003-07-23 | — | — | EP | disclosed |
| CN-1259951-A | Novel pharmaceutically useful compounds | ASTRA PHARMA PROD (GB) | 2000-07-12 | — | — | CN | disclosed |
| US-6028074-A | FOR TREATING ALLOGRAFT REJECTION | ASTRA PHARMACEUTICALS, LTD. (GB) | 2000-02-22 | — | — | US | disclosed |
| US-6028074-A | FOR TREATING ALLOGRAFT REJECTION | ASTRA PHARMACEUTICALS, LTD. (GB) | 2000-02-22 | — | — | US | disclosed |
| EP-0975636-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046606-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-22 | — | — | WO | disclosed |